[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SG11201908351TA - Indole derivatives as efflux pump inhibitors - Google Patents

Indole derivatives as efflux pump inhibitors

Info

Publication number
SG11201908351TA
SG11201908351TA SG11201908351TA SG11201908351TA SG 11201908351T A SG11201908351T A SG 11201908351TA SG 11201908351T A SG11201908351T A SG 11201908351TA SG 11201908351T A SG11201908351T A SG 11201908351TA
Authority
SG
Singapore
Prior art keywords
new jersey
international
suite
new
co7d
Prior art date
Application number
Inventor
Edmond J Lavoie
Ajit Parhi
Yi Yuan
Yongzheng Zhang
Yangsheng Sun
Original Assignee
Edmond J Lavoie
Ajit Parhi
Yi Yuan
Yongzheng Zhang
Yangsheng Sun
Rutgers The State University Of New Jersey
Taxis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Edmond J Lavoie, Ajit Parhi, Yi Yuan, Yongzheng Zhang, Yangsheng Sun, Rutgers The State University Of New Jersey, Taxis Pharmaceuticals Inc filed Critical Edmond J Lavoie
Publication of SG11201908351TA publication Critical patent/SG11201908351TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 13 September 2018 (13.09.2018) WIPO I PCT 0111111010 0111 °nolo mu IIIII Em OH oinio oimIE (10) International Publication Number WO 2018/165611 Al (51) International Patent Classification: CO7D 403/12 (2006.01) CO7D 401/12 (2006.01) CO7D 401/14 (2006.01) CO7D 405/04 (2006.01) A61K 31/404 (2006.01) C07D 209/42 (2006.01) C07D 401/04 (2006.01) A61P 31/04 (2006.01) (21) International Application Number: PCT/US2018/021848 (22) International Filing Date: 09 March 2018 (09.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/469,987 10 March 2017 (10.03.2017) US 62/523,154 21 June 2017 (21.06.2017) US (71) Applicants: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY [US/US]; Old Queens Building, Som- erset and George Streets, New Brunswick, New Jer- sey 08903 (US). TAXIS PHARMACEUTICALS, INC. [US/US]; 9 Deer Park Drive, Suite J-15, Monmouth Junc- tion, New Jersey 08852 (US). (72) Inventors; and (71) Applicants: LAVOIE, Edmond J. [US/US]; Old Queens Building, Somerset and George Streets, New Brunswick, New Jersey 08903 (US). PARHI, Ajit [US/US]; Old Queens Building, Somerset and George Streets, New Brunswick, New Jersey 08903 (US). YUAN, Yi [CN/US]; 9 Deer Park Drive, Suite J-15, Monmouth Junction, New Jersey 08852 (US). ZHANG, Yongzheng [US/US]; 9 Deer Park Drive, Suite J-15, Monmouth Junction, New Jersey 08852 (US). SUN, Yangsheng [US/US]; 9 Deer Park Drive, Suite J-15, Monmouth Junction, New Jersey 08852 (US). (74) Agent: MICKELSON, John W. et al.; 7851 Metro Park- way, Suite 325, Bloomington, Minnesota 55425 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) Published: — with international search report (Art. 21(3)) = (54) Title: INDOLE DERIVATIVES AS EFFLUX PUMP INHIBITORS (57) : Disclosed herein are compounds of formula (I): and salts thereof. Also disclosed are compositions comprising compounds of formula I and compounds of for- mula I for use in treating or preventing bacterial infections. (I) W O 20 18/ 165 6 11 Al
SG11201908351T 2017-03-10 2018-03-09 Indole derivatives as efflux pump inhibitors SG11201908351TA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762469987P 2017-03-10 2017-03-10
US201762523154P 2017-06-21 2017-06-21
PCT/US2018/021848 WO2018165611A1 (en) 2017-03-10 2018-03-09 Indole derivatives as efflux pump inhibitors

Publications (1)

Publication Number Publication Date
SG11201908351TA true SG11201908351TA (en) 2019-10-30

Family

ID=62044950

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201908351T SG11201908351TA (en) 2017-03-10 2018-03-09 Indole derivatives as efflux pump inhibitors

Country Status (12)

Country Link
US (1) US11993571B2 (en)
EP (1) EP3592736A1 (en)
JP (1) JP7323179B2 (en)
KR (1) KR102697360B1 (en)
CN (1) CN110770224B (en)
AU (1) AU2018231120B2 (en)
BR (1) BR112019018691A2 (en)
CA (1) CA3061238A1 (en)
IL (1) IL269210A (en)
MX (1) MX2019010717A (en)
SG (1) SG11201908351TA (en)
WO (1) WO2018165611A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10556854B2 (en) 2016-02-24 2020-02-11 Rutgers, The State University Of New Jersey Bacterial efflux pump inhibitors
US10836706B2 (en) 2016-02-24 2020-11-17 Rutgers, The State University Of New Jersey Bacterial efflux pump inhibitors
WO2018165612A1 (en) 2017-03-10 2018-09-13 Rutgers, The State University Of New Jersey Bacterial efflux pump inhibitors
JP7323179B2 (en) 2017-03-10 2023-08-08 ラトガーズ， ザ ステイト ユニバーシティ オブ ニュー ジャージー Indole derivatives as efflux pump inhibitors
WO2018165614A1 (en) 2017-03-10 2018-09-13 Rutgers, The State University Of New Jersey Bacterial efflux pump inhibitors
WO2018218192A1 (en) 2017-05-26 2018-11-29 Rutgers, The State University Of New Jersey Bacterial efflux pump inhibitors
US11458121B2 (en) 2017-06-26 2022-10-04 Rutgers, The State University Of New Jersey Therapeutic compounds and methods to treat infection
US11845742B2 (en) 2017-11-14 2023-12-19 Rutgers, The State University Of New Jersey Therapeutic compounds and methods to treat infection
KR102704123B1 (en) 2019-11-01 2024-09-06 에스엘 주식회사 Lamp for vehicle

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3238215A (en) * 1963-10-17 1966-03-01 Sterling Drug Inc 1-[(3-, 2-, and 1-indolyl)-lower-alkyl-, lower-alkenyl-, and lower-alkynyl]piperidines
US3465080A (en) * 1968-10-07 1969-09-02 American Cyanamid Co Therapeutic compositions containing morpholinoalkylene - indoles and methods of administering such in the treatment of depression
US3978224A (en) 1975-07-01 1976-08-31 Schering Corporation Antimicrobial halo-substituted-2-cyanoethylaminoalkyl-3-phenyl-indoles
US4910193A (en) * 1985-12-16 1990-03-20 Sandoz Ltd. Treatment of gastrointestinal disorders
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
WO1992004017A1 (en) 1990-09-10 1992-03-19 The Upjohn Company Cis-n-(2-aminocyclohexyl)benzamide and their enantiomers as anticonvulsants
US5864039A (en) * 1994-03-30 1999-01-26 Yoshitomi Pharmaceutical Industries, Ltd. Benzoic acid compounds and use thereof as medicaments
US5663152A (en) 1995-01-19 1997-09-02 Asahi Kasei Kogyo Kabushiki Kaisha Potentiators for aminoglycosides
US6506339B1 (en) * 1997-02-10 2003-01-14 Biomedical Design, Inc. Method of sterilization
US6204279B1 (en) 1998-06-03 2001-03-20 Microcide Pharmaceuticals, Inc. Peptidomimetic efflux pump inhibitors
AU2337599A (en) * 1998-01-23 1999-08-09 Microcide Pharmaceuticals, Inc. Efflux pump inhibitors
IL143535A0 (en) 1998-12-04 2002-04-21 Influx Inc Inhibitors of multidrug transporters
US6730684B1 (en) * 1999-10-08 2004-05-04 Affinium Pharmaceuticals, Inc. Fab I inhibitors
DE60029235T2 (en) * 1999-10-08 2007-06-14 Affinium Pharmaceuticals, Inc., Toronto FAB I INHIBITORS
US6555569B2 (en) 2000-03-07 2003-04-29 Pfizer Inc. Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection
US7365205B2 (en) 2001-06-20 2008-04-29 Daiichi Sankyo Company, Limited Diamine derivatives
HUP0103986A2 (en) * 2001-09-28 2003-06-28 Richter Gedeon Vegyészeti Gyár Rt. New piperidinyl compound having carboxylic acid structures, process for their preparation and pharmaceutical compositions containing them
EP1314733A1 (en) * 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
US7829543B2 (en) 2003-01-07 2010-11-09 Paratek Pharmaceuticals, Inc. Substituted polyamines as inhibitors of bacterial efflux pumps
GB0403038D0 (en) * 2004-02-11 2004-03-17 Novartis Ag Organic compounds
US7994225B2 (en) 2004-03-17 2011-08-09 Rempex Pharmaceuticals, Inc. Bacterial efflux pump inhibitors for the treatment of ophthalmic and otic infections
EP1758920A1 (en) 2004-05-21 2007-03-07 Mpex Pharmaceuticals, Inc. Bacterial efflux pump inhibitors and methods of treating bacterial infections
JP2008520740A (en) 2004-11-23 2008-06-19 ピーティーシー セラピューティクス， インコーポレイテッド Substituted phenols as activators that inhibit VEGF production
US7855228B2 (en) 2005-02-10 2010-12-21 The Board Of Trustees Of The Leland Stamford Junior University Antibiotics targeting MreB
US7807704B2 (en) 2006-03-30 2010-10-05 Chemocentryx, Inc. Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2
FR2904317A1 (en) * 2006-07-27 2008-02-01 Inst Nat Sante Rech Med ANALOGUES OF HALOGENOBENZAMIDES BRANDED AS RADIOPHARMACEUTICALS
DK2068886T3 (en) 2006-10-03 2013-11-18 Tekmira Pharmaceuticals Corp Lipid-containing preparations
AR070398A1 (en) 2008-02-22 2010-03-31 Gruenenthal Chemie INDOL SUBSTITUTED DERIVATIVES
WO2009110002A1 (en) 2008-03-05 2009-09-11 Council Of Scientific & Industrial Research Novel efflux pump inhibitors
EP2346825A2 (en) 2008-09-18 2011-07-27 Evotec AG Modulators of p2x3 receptor activity
US8173636B2 (en) 2009-04-03 2012-05-08 Achillion Pharmaceuticals, Inc. Hydroxylthienoquinolones and related compounds as anti-infective agents
EP2536408A1 (en) 2010-02-16 2012-12-26 Wockhardt Research Centre Efflux pump inhibitors
EP2394653A1 (en) * 2010-05-26 2011-12-14 Almirall, S.A. Topical pharmaceutical compositions comprising mometasone furoate
FR2969150B1 (en) * 2010-12-20 2013-07-26 Centre Nat Rech Scient NOVEL INDOLIC MOLECULES DEMONSTRATING ANTIBACTERIAL ACTIVITIES IN A VARIETY OF GRAM-NEGATIVE AND POSITIVE BACTERIA INCLUDING MULTI-DRUG-RESISTANT BACTERIA
EA028093B1 (en) 2012-09-07 2017-10-31 Новартис Аг Indole carboxamide derivatives and uses thereof
US20150291565A1 (en) 2012-11-13 2015-10-15 Memorial Sloan-Kettering Cancer Center Indole compounds and their use as antimicrobials
US20170044100A1 (en) * 2014-04-22 2017-02-16 The Johns Hopkins University Inhibitors of drug-resistant mycobacterium tuberculosis
SG11201701598PA (en) * 2014-09-10 2017-03-30 Epizyme Inc Smyd inhibitors
US9926261B2 (en) 2015-03-10 2018-03-27 Rutgers, The State University Of New Jersey Bacterial efflux pump inhibitors
US9950993B2 (en) 2015-03-13 2018-04-24 Rutgers, The State University Of New Jersey Bacterial efflux pump inhibitors
JP2018521021A (en) 2015-06-11 2018-08-02 バジリア・ファルマスーチカ・インターナショナル・アーゲーＢａｓｉｌｅａ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ａｇ Efflux pump inhibitors and their therapeutic use
WO2017023894A1 (en) * 2015-08-03 2017-02-09 Raze Therapeutics, Inc. Mthfd2 inhibitors and uses thereof
US10556854B2 (en) 2016-02-24 2020-02-11 Rutgers, The State University Of New Jersey Bacterial efflux pump inhibitors
US10836706B2 (en) 2016-02-24 2020-11-17 Rutgers, The State University Of New Jersey Bacterial efflux pump inhibitors
PL3557998T3 (en) 2016-12-23 2024-03-11 Aquinnah Pharmaceuticals Inc. Compouns, compositions and methods of use
WO2018165612A1 (en) 2017-03-10 2018-09-13 Rutgers, The State University Of New Jersey Bacterial efflux pump inhibitors
JP7323179B2 (en) 2017-03-10 2023-08-08 ラトガーズ， ザ ステイト ユニバーシティ オブ ニュー ジャージー Indole derivatives as efflux pump inhibitors
WO2018165614A1 (en) 2017-03-10 2018-09-13 Rutgers, The State University Of New Jersey Bacterial efflux pump inhibitors
WO2018218192A1 (en) 2017-05-26 2018-11-29 Rutgers, The State University Of New Jersey Bacterial efflux pump inhibitors
US11458121B2 (en) * 2017-06-26 2022-10-04 Rutgers, The State University Of New Jersey Therapeutic compounds and methods to treat infection
US20190031624A1 (en) 2017-07-28 2019-01-31 Rutgers, The State University Of New Jersey Therapeutic compounds and methods to treat infection
US11845742B2 (en) * 2017-11-14 2023-12-19 Rutgers, The State University Of New Jersey Therapeutic compounds and methods to treat infection

Also Published As

Publication number Publication date
MX2019010717A (en) 2019-12-05
CN110770224B (en) 2022-11-18
WO2018165611A1 (en) 2018-09-13
US20210094912A1 (en) 2021-04-01
US11993571B2 (en) 2024-05-28
EP3592736A1 (en) 2020-01-15
BR112019018691A2 (en) 2020-04-07
JP7323179B2 (en) 2023-08-08
JP2020510044A (en) 2020-04-02
IL269210A (en) 2019-11-28
KR20190138790A (en) 2019-12-16
AU2018231120B2 (en) 2022-06-23
CA3061238A1 (en) 2018-09-13
KR102697360B1 (en) 2024-08-20
AU2018231120A1 (en) 2019-10-31
CN110770224A (en) 2020-02-07

Similar Documents

Publication Publication Date Title
SG11201908351TA (en) Indole derivatives as efflux pump inhibitors
SG11201901747VA (en) Inhibitors of cellular metabolic processes
SG11201902938TA (en) Compounds, devices, and uses thereof
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201809714TA (en) Piperidines as menin inhibitors
SG11201808799SA (en) Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors
SG11201808708RA (en) Heterocyclic amides useful as protein modulators
SG11201810983PA (en) Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201808907PA (en) Inhibitors of activin receptor-like kinase
SG11201900947RA (en) Tlr7/8 antagonists and uses thereof
SG11201909083UA (en) Piperidines as covalent menin inhibitors
SG11201900163PA (en) Macrocycle kinase inhibitors
CA2859619C (en) Bromodomain inhibitors
SG11201909429VA (en) 3-(((((2s,5r)-2-carbamoyl-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl)oxy)sulfonyl)oxy)-2,2-dimethylprop noate derivatives and related compounds as perorally administered profrugs of beta-lactamase inhibitors for treating bacterial infections
SG11201803906PA (en) Control of cellular redox levels
SG11201407682TA (en) Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
SG11201906222WA (en) Jak1 selective inhibitors
SG11201901658PA (en) Beta-lactamase inhibitor compounds
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201806544XA (en) Compounds and methods of treating rna-mediated diseases
SG11201908929VA (en) Synthekine compositions and methods of use
SG11201906164RA (en) Bicyclic inhibitors of histone deacetylase
SG11201806133UA (en) Intermediates in the synthesis of eribulin and related methods of synthesis
SG11201811416VA (en) Crystalline solid forms of a bet inhibitor
SG11201811686UA (en) 18f-labeled triazole containing psma inhibitors